Longitudinal Performance of the Psoriasis Epidemiology Screening Tool (PEST) in Canada and Latin America: Results from the Prospective, Observational, 5-Year PURE Registry - Summary - MDSpire
Advertisement
Long-Term Evaluation of the Psoriasis Epidemiology Screening Tool (PEST) in Canada and Latin America: Findings from the 5-Year Prospective PURE Registry Study
To evaluate the performance of the PEST questionnaire in identifying patients with psoriasis at risk for psoriatic arthritis (PsA) over a 5-year period.
Approach:
Study Design: A prospective, observational cohort study conducted in over 60 sites across Canada and Latin America, enrolling patients with moderate to severe psoriasis.
Patient Assessment: Participants completed the PEST questionnaire at baseline and every 6 months for 5 years.
Key Findings:
Many patients initially PEST negative at baseline became PEST positive over 5 years.
The PEST questionnaire demonstrated good sensitivity and specificity for identifying patients at risk of PsA.
The study reinforces the utility of the PEST questionnaire as a standardized instrument in clinical practice.
Interpretation:
Limitations:
The results may not be generalizable beyond the enrolled population in the PURE registry.
The PEST scores were not reported to treating physicians, which may affect clinical follow-up.
Conclusion:
The study confirms the PEST questionnaire's effectiveness in longitudinal monitoring of psoriasis patients for PsA risk.
by Jennifer Beecker, Lorne Albrecht, Ignacio Dei-Cas, Melinda Gooderham, Charles Lynde, Kim A. Papp, Paul Keown, Antonio Vieira, Mahmoud S. Farag, Marie Maguin, Tanya Zappitelli, Philip S. Helliwell
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
